RT Journal Article
SR Electronic
T1 Delayed Radiotherapy for Patients with Localized Prostate Cancer: Validation by Propensity Score Matching
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1629
OP 1633
VO 33
IS 4
A1 NAKAYAMA, HIDETSUGU
A1 KANEMOTO, AYAE
A1 KIKUCHI, KOJI
A1 MATSUKI, KATSUYUKI
A1 TOMOBE, MITSURO
A1 TSUKAMOTO, SADAMU
A1 TAKESHIMA, HITOSHI
A1 OSHIRO, YOSHIKO
A1 SUGAHARA, SHINJI
A1 TOKUUYE, KOICHI
YR 2013
UL http://ar.iiarjournals.org/content/33/4/1629.abstract
AB Aim: To retrospectively investigate the biochemical outcome following delayed radiotherapy in patients with prostate cancer. Patients and Methods: From July 2000 to November 2008, 144 consecutive patients with localized prostate cancer underwent radiotherapy and androgen-deprivation therapy. Biochemical progression-free survival was compared in patients who began radiotherapy >6 months (delayed group) with these who began ≤6 months (non-delayed group) from diagnosis by biopsy. Treatment selection bias was adjusted by the propensity score method. Results: After a median follow-up of 64 months, the 5-year biochemical progression-free survival of the delayed and non-delayed groups was 87.4% (95% confidence interval, CI=69.7-95.1%) and 96.6% (95% CI=89.6-98.9%), respectively (p=0.03). Delayed radiotherapy was the only independent risk factor for biochemical progression (hazard ratio=3.97, 95% CI 1.07-14.7, p=0.04). The results were validated by propensity score analysis. Conclusion: Delaying radiotherapy by >6 months increases the risk of biochemical progression in patients with localized prostate cancer.